Patents Examined by Patrick Lewis
  • Intestinal environment-improving agent
    Patent number: 9364017
    Abstract: An intestinal environment-improving agent containing, as an effective component, a starch with a high resistant starch content that satisfies the following conditions (a), (b), (c), and (d): (a) a content of a resistant starch measured by the resistant starch measurement method of AOAC official method 2002. 02 is equal to or higher than 60%; (b) a peak of a molecular weight is equal to or higher than 6×103 and equal to or lower than 4×104; (c) a molecular weight dispersity is equal to or higher than 1.5 and equal to or higher than 6.0; and (d) a gelatinization enthalpy at 50° C. to 130° C. measured by a differential scanning calorimetry is equal to or lower than 10 J/g.
    Type: Grant
    Filed: February 19, 2013
    Date of Patent: June 14, 2016
    Assignee: J-OIL MILLS, INC.
    Inventors: Yuya Nagahata, Isao Kobayashi, Masaru Goto
  • Process for the production of acetic acid and dimethyl ether
    Patent number: 9365483
    Abstract: Process for producing acetic acid and dimethyl ether by contacting a mixture of methanol and methyl acetate with a zeolite catalyst. The zeolite has a 2-dimensional channel system having at least one channel with a 10-membered ring and containing at least 5% of its cation exchange capacity occupied by one or more alkali metal cations.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: June 14, 2016
    Assignee: BP CHEMICALS LIMITED
    Inventors: Thomas Edward Clark, John Glenn Sunley
  • Method for purifying glucose polymers for peritoneal dialysis solutions
    Patent number: 9353192
    Abstract: The invention relates to a method of purifying glucose polymers for the production of peritoneal dialysis solutions, characterized in that it includes at least one step of processing activated carbon and/or granular black, at least one sterilizing filtration step, at least one heat treatment step, and at least one ultrafiltration step.
    Type: Grant
    Filed: April 29, 2010
    Date of Patent: May 31, 2016
    Assignee: ROQUETTE FRERES
    Inventors: Marc Biguet, Stéphane Bourdain, Pierrick Duflot
  • Methods for treating cancer and non-neoplastic conditions
    Patent number: 9351964
    Abstract: Compounds, such as compounds of Formula (I), that selectively inhibit pathological production of human vascular endothelial growth factor (VEGF) and compositions comprising such Compounds are described. Compounds that inhibit viral replication or the production of viral RNA or DNA or viral protein and compositions comprising such Compounds are described. Also described are methods of reducing VEGF using such Compounds and methods for treating cancer and non-neoplastic conditions involving the administration of such Compounds. Further described are methods of inhibiting viral replication or the production of viral RNA or DNA or viral protein using such Compounds and methods for treating viral infections involving the administration of such Compounds. The Compounds may be administered as a single agent therapy or in combination with one or more additional therapies to a human in need of such treatments.
    Type: Grant
    Filed: May 27, 2010
    Date of Patent: May 31, 2016
    Assignee: PTC Therapeutics, Inc.
    Inventors: Neil Almstead, Tamil Arasu, Soongyu Choi, Liangxian Cao, Jeffrey Allen Campbell, Donald Corson, Thomas W. Davis, Jason D. Graci, Zhengxian Gu, Peter Seongwoo Hwang, William Lennox, Harry H. Miao, Langdon Miller, Young-Choon Moon, Hongyan Qi, Christopher Trotta, Marla L. Weetall
  • Carbohydrate conjugates as delivery agents for oligonucleotides
    Patent number: 9352048
    Abstract: The present invention provides iRNA agents comprising at least one subunit of the formula (I): wherein: A and B are each independently for each occurrence O, N(RN) or S; X and Y are each independently for each occurrence H, OH, a hydroxyl protecting group, a phosphate group, a phosphodiester group, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, —P(Z?)(Z?)O-nucleoside, —P(Z?)(Z?)O-oligonucleotide, a lipid, a PEG, a steroid, a lipophile, a polymer, —P(Z?)(Z?)O-Linker-OP(Z??)(Z?)O-oligonucleotide, a nucleotide, an oligonucleotide, —P(Z?)(Z?)-formula (I), —P(Z?)(Z?)- or -Linker-R; R is LG, -Linker-LG, or has the structure shown below: LG is independently for each occurrence a carbohydrate, e.g.
    Type: Grant
    Filed: July 22, 2014
    Date of Patent: May 31, 2016
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Jayaprakash Nair, Martin Maier
  • Amino sugar-bound anti-cancerous noble metal complex
    Patent number: 9346849
    Abstract: Disclosed is a pharmaceutical composition containing as an active ingredient a compound represented by formula (I) or a physiologically acceptable salt thereof, and a method for treating cancer, the method including administering the compound represented by formula (I) or the physiologically acceptable salt thereof.
    Type: Grant
    Filed: January 29, 2013
    Date of Patent: May 24, 2016
    Assignee: NATIONAL UNIVERSITY CORPORATION NARA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Shigenobu Yano, Takashi Shibahara, Shunichiro Ogura
  • Solid forms of an antiviral compound
    Patent number: 9340568
    Abstract: Crystalline solid forms of the anti-HCV compound (S)-isopropyl 2-((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2- yl)methoxy)(phenoxy)phosphorylamino)propanoate (Compound I) are described Also provided are processes of making and methods of using the crystalline forms.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: May 17, 2016
    Assignee: GILEAD PHARMASSET LLC
    Inventors: Melissa Jean Casteel, Kathleen Dashner, Hyuk-Jun Jung, Mun Sik Seo, Bing Shi, Fang Wang, Vahid Zia
  • Process for preparing polysaccharide fibers from aqueous alkali metal hydroxide solution
    Patent number: 9334584
    Abstract: This invention pertains to a novel processing for preparing fibers from poly(?(1?3)glucan). The fibers prepared according to the invention, have “cotton-like” properties, are useful in textile applications, and can be produced as continuous filaments on a year-round basis. The process comprises solution spinning a 5-20% solids concentration of poly(?(1?3)glucan) in an aqueous alkali metal hydroxide, in particular NaOH at concentration of 2 to 10 weight-%, and coagulating the spun fiber in an acid coagulation liquid.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: May 10, 2016
    Assignee: E I DU PONT DE NEMOURS AND COMPANY
    Inventors: John P. O'Brien, Kathleen Opper
  • Uridine and uridine analogues for treatment of specific lung diseases, namely COPD and pulmonary fibrosis
    Patent number: 9333216
    Abstract: The present invention relates to the new indications of chronic obstructive pulmonary disease (COPD) and idiophathic lung fibrosis (IPF) for uridine and uridine analogues.
    Type: Grant
    Filed: July 24, 2012
    Date of Patent: May 10, 2016
    Assignee: Universitaetsklinikum Freiburg
    Inventors: Marco Idzko, Stephan Sorichter
  • Purification of nucleic acids
    Patent number: 9328342
    Abstract: The present invention solves the problem of isolating nucleic acids from cells in the presence of the growth medium. The invention is particularly useful for isolating extrachromosomal replicons such as plasmids. Cells are lysed in the presence of the medium in which they were grown and nucleic acids are isolated using a pipette tip column. A liquid handling robot can be used to isolate nucleic acids from multiple samples simultaneously without the need for human intervention.
    Type: Grant
    Filed: August 25, 2014
    Date of Patent: May 3, 2016
    Assignee: PhyNexus, Inc.
    Inventors: Chris Suh, Lee Hoang, Douglas T. Gjerde, Carrie Loan Kim Huynh
  • Compositions and methods for treating retinal degradation
    Patent number: 9326983
    Abstract: The present disclosure relates to compositions and methods for treating retinal damage and/or retinal degradation. More specifically, this disclosure relates to methods for treating degradation of the retinal pigment epithelium by administering compositions comprising a nucleoside and/or a nucleoside or nucleotide reverse transcriptase inhibitor.
    Type: Grant
    Filed: August 1, 2014
    Date of Patent: May 3, 2016
    Assignee: University of Kentucky Research Foundation
    Inventors: Jayakrishna Ambati, Benjamin Fowler
  • Regulators of aldehyde dehydrogenase ALDH3A1 and related therapeutic methods
    Patent number: 9320722
    Abstract: Described herein are compositions and methods for the treatment of cancer, and in particular cancers characterized by a high level of ALD3H1 activity, which is associated with chemoresistance to cancer chemotherapeutic agents that are degraded by ALD3H1. The compositions described herein act as competitive inhibitors of ALD3H1 and thereby reduce breakdown of chemotherapeutics by this enzyme, and increase their efficacy for cancer treatment.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: April 26, 2016
    Assignee: Indiana University Research and Technology Corporation
    Inventor: Thomas D. Hurley
  • Method for isolating nucleic acids and composition used therefor
    Patent number: 9315800
    Abstract: The disclosure provides a composition and method for isolating nucleic acids, in which the composition includes at least one halocarbon, at least one salt and at least one surfactant. Mixing the composition and a biosample to form a homogenized solution, nucleic acids in the solution can be easily isolated with a simple treatment and good yield.
    Type: Grant
    Filed: August 9, 2013
    Date of Patent: April 19, 2016
    Assignee: Industrial Technology Research Institute
    Inventors: Yi-Chang Chen, Jane S-C Tsai
  • Therapeutic agent for inflammatory diseases, containing adenosine N1-oxide as an effective ingredient
    Patent number: 9301968
    Abstract: The present invention has an object to provide an effective and safe therapeutic agent for inflammatory diseases such as sepsis, hepatitis, and inflammatory bowel disease, and solves the above object by providing a therapeutic agent for inflammatory diseases containing adenosine N1-oxide or a derivative thereof as an effective ingredient.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: April 5, 2016
    Assignee: HAYASHIBARA CO., LTD.
    Inventors: Keizo Kohno, Emiko Ohashi, Hajime Kusano, Shigeharu Fukuda, Tatsuya Ishihara
  • Processes and intermediates for preparing anti-HIV agents
    Patent number: 9296779
    Abstract: The invention provides synthetic processes and synthetic intermediates that can be used to prepare compounds having useful anti-HIV properties.
    Type: Grant
    Filed: February 5, 2015
    Date of Patent: March 29, 2016
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Richard Hung Chiu Yu, Brandon Heath Brown, Richard P. Polniaszek, Benjamin R. Graetz, Keiko Sujino, Duong Duc-Phi Tran, Alan Scott Triman, Kenneth M. Kent, Steven Pfeiffer
  • Methods, assays and compounds for treating bacterial infections by inhibiting methylthioinosine phosphorylase
    Patent number: 9290501
    Abstract: The present invention discloses methods for treating bacterial infections in a subject comprising administering to the subject a sub-growth inhibiting amount of a 5?-methylthioinosine phosphorylase (MTIP) inhibitor, as well as assays for identifying such inhibitors, and compounds and pharmaceutical compositions comprising the inhibitors.
    Type: Grant
    Filed: November 28, 2011
    Date of Patent: March 22, 2016
    Assignees: Albert Einstein College of Medicine, Inc., Victoria Link Limited
    Inventors: Vern L. Schramm, Keith Clinch, Peter Charles Tyler, Gary Brian Evans, Richard Hubert Furneaux
  • Oligonucleotide synthesis method using highly dispersible liquid-phase support
    Patent number: 9284344
    Abstract: A nucleic acid synthesis method enabling a reaction in a fluid (flow) with a highly dispersible liquid-phase support to improve coupling efficiency is provided. The method for synthesizing an oligonucleotide comprising: sequentially condensing and oxidizing a nucleoside phosphoramidite compound in the presence of an acid/azole complex compound using a starting raw material, i.e.
    Type: Grant
    Filed: May 30, 2012
    Date of Patent: March 15, 2016
    Assignee: HOKKAIDO SYSTEM SCIENCE CO., LTD.
    Inventors: Shokaku Kim, Masanori Matsumoto
  • Sialic acid dimers
    Patent number: 9260467
    Abstract: Sialic acid derivatives of the formula (I) in which the symbols have the definitions stated in the description are suitable as medicaments, more particularly for diseases whose course is influenced by Siglec ligands.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: February 16, 2016
    Inventors: Reinhard Brossmer, Horst Prescher
  • Process for perparing fondaparinux sodium and intermediates useful in the synthesis thereof
    Patent number: 9255119
    Abstract: Processes for the synthesis of the Factor Xa anticoagulent Fondaparinux, and related compounds are described. Also described are protected pentasaccharide intermediates as well as efficient and scalable processes for the industrial scale production of Fondaparinux sodium by conversion of the protected pentasaccharide intermediates via a sequence of deprotection and sulfonation reactions.
    Type: Grant
    Filed: April 18, 2014
    Date of Patent: February 9, 2016
    Assignee: RELIABLE BIOPHARMACEUTICAL CORPORATION
    Inventors: Sourena Nadji, James T. Smoot, Joseph A. Vanartsdalen
  • Deuterated rigosertib
    Patent number: 9249093
    Abstract: This invention relates to novel substituted styryl benzylsulfones that are multikinase inhibitors and pharmaceutically acceptable acid addition salts thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by an agent that inhibits kinases, such as phosphatidylinositol 3-kinase (PI3-K) and polo-like kinase (PLK-1).
    Type: Grant
    Filed: April 19, 2013
    Date of Patent: February 2, 2016
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Roger D. Tung